CHANGCHUN BCHT BIOTECHNOLOGY CO revenue breakdown overview

CHANGCHUN BCHT BIOTECHNOLOGY CO revenue for the last year amounted to 1.23 B CNY, the most of which — 837.39 M CNY — came from its highest performing source at the moment, Chickenpox Vaccine, the year earlier bringing 819.64 M CNY. The greatest contribution to the revenue figure was made by China — last year it brought CHANGCHUN BCHT BIOTECHNOLOGY CO 1.20 B CNY, and the year before that — 1.79 B CNY.